In an amicus brief submitted to the Supreme Court, AAM called on the court to reject one form of patent system manipulation attempted by a brand-name drug company. AAM’s brief emphasizes the extent to which Helsinn’s interpretation of the on-sale bar would invite manipulation and foster confusion in the pharmaceutical market, with deleterious consequences for patients, taxpayers, and others who seek more affordable medicines.
